Merck's Sac-TMT Lowers Risk of Death 32% in Advanced Endometrial Cancer Trial

12:36 PM EDT, 10/26/2026 (MT Newswires) -- Merck (MRK) said Monday that an interim analysis of the phase 3 TroFuse-005 trial showed statistically significant and clinically meaningful improvements in overall survival and progression-free survival among patients with advanced or recurrent endometrial cancer treated with sacituzumab tirumotecan. The treatment reduced the risk of death by 32% and the risk of disease progression or death by 41% compared with treatment of physician's choice. It also improved the key secondary endpoint of objective response rate compared with treatment of physician's choice. Sac-TMT, developed with Kelun-Biotech, is being studied in patients whose endometrial cancer progressed after chemotherapy and immunotherapy. The FDA has accepted Merck's application for priority review, with a decision expected by June 15, 2027. Price: 141.38, Change: -3.89, Percent Change: -2.68